Compositions and methods for enhancement of major histocompatibility complex class I restricted antigen presentation
View Patent ↗Compositions and methods for eliciting an in vivo cytotoxic lymphocyte (CTL) response against a modified soluble protein antigen are disclosed. The modified soluble protein antigen comprises an added peptidic sequence which facilitates entry of the modified antigen into antigen presenting cells (APC).
1. A composition, comprising an antigen presenting cell (APC), stimulated by exposure “in vitro” to a modified antigen having an added peptidic sequence consisting of SEQ ID NO:2, wherein said stimulated APC is effective to activate T-cells to produce a cytotoxic cellular immune response against said antigen, at a T-cell activation level that is higher than that produced by such APC stimulated by the antigen alone.
2. The composition of claim 1 , wherein said antigen is a soluble protein antigen.
3. The composition of claim 1 , for use in immunizing a subject against a tumor or pathogen wherein said antigen is specific to the tumor or pathogen.
4. The composition of claim 1 , wherein said added peptidic sequence is covalently linked to said antigen.
5. The composition of claim 1 , wherein said antigen is a fusion protein produced by translation of a continuous nucleotide coding sequence.